Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. (Q64937145)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 June 2010

Language	Label	Description	Also known as
English	Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.	scientific article published on 18 June 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. (English)

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

3

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

author name string

Ian H Gabriel

1

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Ruhena Sergeant

2

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Jane F Apperley

4

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Hugues DeLavallade

5

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Abdullah Alsuliman

6

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Ahmad Khoder

7

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

David Marin

8

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Edward Kanfer

9

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Nichola Cooper

10

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

John Davis

11

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Donald MacDonald

12

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Marco Bua

13

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Letizia Foroni

14

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Chrissy Giles

15

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Dragana Milojkovic

16

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Amin Rahemtulla

17

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Katayoun Rezvani

18

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

language of work or name

0 references

publication date

18 June 2010

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

116

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

12

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

2033-2039

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Natural killer cell signaling pathways

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MHC class I molecules and KIRs in human history, health and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Missing ligand model in autologous stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulatory T cells and inhibitory cytokines in autoimmunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How I treat multiple myeloma in younger patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of high-dose therapy with autologous stem cell support in the era of novel agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and proliferation factors of normal and malignant plasma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epigenetic control of highly homologous killer Ig-like receptor gene alleles

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NK cell recognition

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of autologous and allogeneic stem cell transplantation in myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib in the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20562327

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2010-03-273706

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6143153

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64937145&oldid=1406235595"